Drug Free Solution Stock Net Income
| DSOL Stock | USD 0 0.00 0.00% |
As of the 5th of February, Drug Free shows the Variance of 11.27, mean deviation of 0.8139, and Standard Deviation of 3.36. Drug Free Solution technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Drug Free Solution market risk adjusted performance and total risk alpha to decide if Drug Free Solution is priced favorably, providing market reflects its regular price of 0.0014 per share. As Drug Free Solution appears to be a penny stock we also advise to verify its information ratio numbers.
Drug Free's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Drug Free's valuation are provided below:Drug Free Solution does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Drug |
Drug Free 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Drug Free's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Drug Free.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Drug Free on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Drug Free Solution or generate 0.0% return on investment in Drug Free over 90 days. Drug Free is related to or competes with Novacyt SA, Medical Developments, Leef Brands, Sernova Corp, Theralase Technologies, and Cynata Therapeutics. Drug Free Solution, Inc., a lifestyle company, delivers proprietary emotional wellness technology, known as Living Breat... More
Drug Free Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Drug Free's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Drug Free Solution upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1039 | |||
| Maximum Drawdown | 27.27 |
Drug Free Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Drug Free's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Drug Free's standard deviation. In reality, there are many statistical measures that can use Drug Free historical prices to predict the future Drug Free's volatility.| Risk Adjusted Performance | 0.0983 | |||
| Jensen Alpha | 0.3546 | |||
| Total Risk Alpha | 0.1544 | |||
| Treynor Ratio | 0.4523 |
Drug Free February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0983 | |||
| Market Risk Adjusted Performance | 0.4623 | |||
| Mean Deviation | 0.8139 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 3.36 | |||
| Variance | 11.27 | |||
| Information Ratio | 0.1039 | |||
| Jensen Alpha | 0.3546 | |||
| Total Risk Alpha | 0.1544 | |||
| Treynor Ratio | 0.4523 | |||
| Maximum Drawdown | 27.27 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
Drug Free Solution Backtested Returns
Drug Free appears to be out of control, given 3 months investment horizon. Drug Free Solution secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Drug Free Solution, which you can use to evaluate the volatility of the firm. Please utilize Drug Free's Variance of 11.27, standard deviation of 3.36, and Mean Deviation of 0.8139 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Drug Free holds a performance score of 10. The firm shows a Beta (market volatility) of 0.89, which means possible diversification benefits within a given portfolio. Drug Free returns are very sensitive to returns on the market. As the market goes up or down, Drug Free is expected to follow. Please check Drug Free's treynor ratio and day median price , to make a quick decision on whether Drug Free's price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Drug Free Solution has no correlation between past and present. Overlapping area represents the amount of predictability between Drug Free time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Drug Free Solution price movement. The serial correlation of 0.0 indicates that just 0.0% of current Drug Free price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Drug Free Solution reported net income of (755,868). This is 100.22% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.13% higher than that of the company.
Drug Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Drug Free's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Drug Free could also be used in its relative valuation, which is a method of valuing Drug Free by comparing valuation metrics of similar companies.Drug Free is currently under evaluation in net income category among its peers.
Drug Fundamentals
| Return On Asset | -12.7 | |||
| Operating Margin | (413.00) % | |||
| Current Valuation | 496.08 K | |||
| Shares Outstanding | 35.94 M | |||
| Price To Earning | (1.56) X | |||
| Price To Sales | 239.51 X | |||
| Gross Profit | (171.22 K) | |||
| EBITDA | (862.83 K) | |||
| Net Income | (755.87 K) | |||
| Cash And Equivalents | 7.12 K | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (692.31 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -4.9 | |||
| Market Capitalization | 503.2 K | |||
| Total Asset | 11.79 K | |||
| Retained Earnings | (1.68 M) | |||
| Working Capital | (384 K) | |||
| Current Asset | 7 K | |||
| Current Liabilities | 391 K | |||
| Net Asset | 11.79 K |
About Drug Free Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Drug Free Solution's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Drug Free using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Drug Free Solution based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Drug Pink Sheet
Drug Free financial ratios help investors to determine whether Drug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Drug with respect to the benefits of owning Drug Free security.